Jul. 4 at 8:38 AM
$TNON
-FDA clearance
-CTB ~900%
-Offering completed
-Cash runway improved after the offering
-No debt
~22M shares outstanding (still considered a micro float)
-High number of FTDs (Reg SHO Threshold List for 5+ days)
~5–10% short interest
-Nasdaq equity compliance regained after the offering → potential compliance/extension PR
-
$1 bid price deficiency deadline: August 24, 2026
-Shareholder meeting on July 23 (reverse split vote)
-29 granted patents, with additional patents expected in 2026
-Strong earnings report; annual net loss but beat expectations
-Revenue growth
-Expanding product portfolio and indications
-Multiple near-term catalysts
-No immediate financing overhang after the completed offering